Passage BIO, Inc. files 10-Q

Passage Bio reported a net loss of $7.6 million for the first quarter of 2026, a decrease from a $15.4 million loss in the same period last year, driven by lower operating expenses. The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient cash to fund operations over the next 12 months.